Chicago Partners Investment Group LLC increased its stake in Danaher Co. (NYSE:DHR) by 394.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,953 shares of the conglomerate’s stock after buying an additional 3,153 shares during the period. Chicago Partners Investment Group LLC’s holdings in Danaher were worth $339,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in the stock. ETRADE Capital Management LLC increased its stake in shares of Danaher by 5.1% during the second quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after purchasing an additional 917 shares in the last quarter. Honeywell International Inc. bought a new position in shares of Danaher during the second quarter valued at approximately $25,317,000. Roundview Capital LLC increased its stake in shares of Danaher by 2.0% during the second quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after purchasing an additional 502 shares in the last quarter. Eastern Bank increased its stake in shares of Danaher by 4,291.1% during the second quarter. Eastern Bank now owns 128,001 shares of the conglomerate’s stock valued at $10,802,000 after purchasing an additional 125,086 shares in the last quarter. Finally, Perkins Coie Trust Co increased its stake in shares of Danaher by 2.0% during the second quarter. Perkins Coie Trust Co now owns 29,431 shares of the conglomerate’s stock valued at $2,484,000 after purchasing an additional 586 shares in the last quarter. 76.32% of the stock is owned by institutional investors.
In related news, CFO Daniel L. Comas sold 88,184 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $91.02, for a total value of $8,026,507.68. Following the sale, the chief financial officer now owns 227,816 shares in the company, valued at $20,735,812.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Donald J. Ehrlich sold 10,578 shares of the firm’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the sale, the director now owns 104,621 shares in the company, valued at approximately $9,501,679.22. The disclosure for this sale can be found here. Insiders sold 273,810 shares of company stock worth $25,218,813 in the last 90 days. 12.20% of the stock is currently owned by corporate insiders.
Shares of Danaher Co. (NYSE DHR) opened at $94.00 on Friday. The firm has a market cap of $65,390.00, a P/E ratio of 24.16, a P/E/G ratio of 2.24 and a beta of 1.02. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. Danaher Co. has a 1 year low of $77.66 and a 1 year high of $94.82.
Danaher (NYSE:DHR) last announced its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. The company had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.87 earnings per share. research analysts forecast that Danaher Co. will post 3.99 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s dividend payout ratio is currently 16.67%.
A number of equities analysts have weighed in on DHR shares. Citigroup raised their target price on shares of Danaher to $107.00 and gave the company a “buy” rating in a research note on Friday. Goldman Sachs Group reaffirmed a “neutral” rating and set a $83.00 target price on shares of Danaher in a research note on Tuesday, September 26th. Credit Suisse Group raised their target price on shares of Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a research note on Friday, October 20th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $95.00 target price on shares of Danaher in a research note on Friday, September 8th. Finally, Robert W. Baird raised their price target on shares of Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $94.05.
ILLEGAL ACTIVITY WARNING: This article was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thelincolnianonline.com/2017/12/17/chicago-partners-investment-group-llc-grows-position-in-danaher-co-dhr.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.